CHA Vaccine Research Institute, an affiliate of CHA Biotech, received approval from the Ministry of Food and Drug Safety for a phase 1 clinical trial plan (IND) for the recombinant protein shingles vaccine candidate ‘CVI-VZV-001’.
In this clinical trial, CHA Vaccine Research Institute evaluated the safety and tolerability of CVI-VZV-001 by dose in 24 healthy adults aged 50 to 65 years, and evaluated the maximum administered dose, recommended dose for phase 2 clinical trials, and immune response. We plan to observe Wonseong, etc.
CVI-VZV-001 is a recombinant protein shingles vaccine based on the immune enhancement platform ‘Lipo-pam™’ developed by CHA Vaccine Research Institute. Lipo-Pharm prevents shingles by inducing a cellular immune response and inhibiting the activation of the latent herpes zoster virus.
Shingles occurs when the varicella-zoster virus lies dormant in the ganglia and the immune system is weakened. Currently, two types of preventive vaccines have been commercialized, including live attenuated vaccines and recombinant protein vaccines. Among them, the live attenuated vaccine is evaluated as having a lack of protective effect in the elderly, while the currently released recombinant protein vaccine has an excellent protective effect even in the elderly, but has the disadvantage that the adjuvant contained in the vaccine causes severe pain.
The immune-boosting substance applied to CVI-VZV-001 is also used in the chronic hepatitis B treatment vaccine currently in phase 2b in Korea, but there are no reports of serious pain. CHA Vaccine Research Institute’s recombinant protein vaccine is expected to suppress ‘postherpetic neuralgia (PHN)’ by maximizing the cellular immune response in the body.
Jeong-seon Yeom, CEO of CHA Vaccine Research Institute, said, “CVI-VZV-001 is expected to improve the preventive effect by improving the problems of existing vaccines by applying the immune enhancement platform technology independently developed by CHA Vaccine Research Institute.” He added, “This phase 1 clinical trial “We will do our best to expedite product commercialization by quickly conducting clinical trials starting with approval.”
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asian Innovation Hub Pangyo Techno Valley 2022’ news